Literature DB >> 10731624

Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

H R Kranzler1, V Modesto-Lowe, J Van Kirk.   

Abstract

This study compared the effects of nefazodone, a serotonergic antidepressant, with the opioid antagonist naltrexone, and an inactive placebo in 183 alcohol-dependent subjects receiving weekly relapse prevention psychotherapy. Following a single-blind, placebo lead-in period, subjects were randomly assigned to receive study medication, which they took under double-blind conditions for 11 weeks. Naltrexone treatment was associated with significantly more adverse neuropsychiatric and gastrointestinal effects, poorer compliance, and a greater rate of treatment attrition. There were no reliable between-group differences in drinking behavior. These results indicate that nefazodone is not efficacious for treatment of alcohol dependence. Furthermore, the clinical utility of naltrexone seems to be limited by its adverse effects, a finding that has important implications for efforts to develop medications to treat alcohol dependence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10731624     DOI: 10.1016/S0893-133X(99)00135-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  52 in total

1.  Novel 3-O-pegylated carboxylate and 3-O-pegylated carbamate prodrugs of naltrexone for microneedle-enhanced transdermal delivery.

Authors:  Thirupathi Reddy Yerramreddy; Mikolaj Milewski; Narsimha Reddy Penthala; Audra L Stinchcomb; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2010-04-18       Impact factor: 2.823

2.  New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials.

Authors:  Ralitza Gueorguieva; Ran Wu; Brian Pittman; Joyce Cramer; Robert A Rosenheck; Stephanie S O'malley; John H Krystal
Journal:  Biol Psychiatry       Date:  2007-01-16       Impact factor: 13.382

3.  The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.

Authors:  Aron N Starosta; Robert F Leeman; Joseph R Volpicelli
Journal:  J Psychiatr Pract       Date:  2006-03       Impact factor: 1.325

4.  The placebo effect in clinical trials for alcohol dependence: an exploratory analysis of 51 naltrexone and acamprosate studies.

Authors:  Raye Z Litten; I-Jen P Castle; Daniel Falk; Megan Ryan; Joanne Fertig; Chiung M Chen; Hsiao-ye Yi
Journal:  Alcohol Clin Exp Res       Date:  2013-07-24       Impact factor: 3.455

5.  Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study.

Authors:  Spencer Bujarski; James MacKillop; Lara A Ray
Journal:  Exp Clin Psychopharmacol       Date:  2012-03-19       Impact factor: 3.157

6.  [Combination treatment with SSRI and cognitive behavior therapy for relapse prevention of alcohol-dependent men. Results of a randomized, controlled multicenter therapeutic study].

Authors:  M Hautzinger; H Wetzel; A Szegedi; A Scheurich; B Lörch; P Singer; D Schläfke; H Sittinger; T Wobrock; M J Müller; I Anghelescu
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

7.  Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone.

Authors:  Omathanu Pillai; Mohamed O Hamad; Peter A Crooks; Audra L Stinchcomb
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

8.  Effects of naltrexone on cortisol levels in heavy drinkers.

Authors:  Lara A Ray; James Mackillop; Lorenzo Leggio; Marilee Morgan; Kent E Hutchison
Journal:  Pharmacol Biochem Behav       Date:  2008-09-13       Impact factor: 3.533

Review 9.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

Review 10.  How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?

Authors:  Sherry A McKee; Andrea H Weinberger
Journal:  Annu Rev Clin Psychol       Date:  2012-11-13       Impact factor: 18.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.